Clinical trials: Respiratory Infections
COVID-19
Study of Efficacy of Different Treatment Regimens of Olokizumab
The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation.
- Trial name
- RESET (NCT05187793)
- Testing
- Olokizumab, Standard therapy
- Where
- 5 sites in Russia
- Volunteers
- 198 people
- Sponsor
- R-Pharm
Cystic Fibrosis
Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
The purpose of this study is to evaluate the long term safety and tolerability of Liposomal Amikacin for Inhalation (LAI) 590 mg once daily (QD) in Cystic Fibrosis patients with chronic infection due to pseudomonas aeruginosa.
- Trial name
- NCT01316276
- Testing
- Liposomal amikacin for inhalation
- Where
- 50 sites in Austria, Belgium and 15 more
- Volunteers
- 206 people
- Sponsor
- Insmed Incorporated
Elderly, Periodontal Disease
Oral Hygiene Assistance Training Program
This is an oral health study with a nursing home staff training program and product intervention.
- Conditions
- Elderly, Periodontal Disease, Gingivitis, Caries,Dental
- Trial name
- NCT07807397
- Testing
- Stannous Fluoride Toothpaste (SnF), sodium fluoride 5000 ppm, cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwash
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Acute Bronchitis
A Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of CANIUM Tab. in Acute Bronchitis Patients.
This study compared two oral medicines containing Pelargonium sidoides extract in patients aged 12 to 75 years with acute bronchitis.
- Trial name
- NCT07835620
- Testing
- DSP2505(Canium), Umckamin
- Where
- 12 sites in South Korea
- Volunteers
- 223 people
- Sponsor
- Dasan Pharmaceutical Co., Ltd.
COVID-19
Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey
This is a randomized, double-blinded, and positive-controlled Phase IIb clinical trial of COVID-19 vaccine (CoronaVac®) manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate the…
- Trial name
- NCT05150496
- Testing
- Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated, High-dose COVID-19 Vaccine(Vero Cell),Inactivated
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Healthy
Assessing Choice in the Employer Setting (ACES) Study
The purpose of this study is to determine, among adults and in the total population, the effects of offering a choice of FluMist or trivalent inactivated vaccine (TIV) in the employer setting when compared to a control group.
- Trial name
- MA181 (NCT00808808)
- Testing
- Choice of TIV or FluMist with baseline advertisement, Choice of TIV or FluMist with enhanced advertisement and incentives, Control - Usual care offering TIV only with baseline advertisement
- Where
- 47 sites in United States
- Volunteers
- 4,411 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Covid-19 Prevention
A Study of Ad26.COV2.S in Adults (COVID-19)
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination…
- Trial name
- NCT04436276
- Testing
- Ad26.COV2.S
- Where
- 12 sites in United States, Belgium
- Volunteers
- 1,085 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19, Coronavirus
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning
The purpose of this study was to assess the performance of a machine learning algorithm which identifies patients for whom hydroxychloroquine treatment is associated with predicted survival.
- Conditions
- COVID-19, Coronavirus, Mortality
- Trial name
- IDENTIFY (NCT04423991)
- Testing
- COViage
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Dascena
CoronaVirus Disease-2019 (COVID-19)
Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- NCT04644120
- Testing
- ABBV-47D11, ABBV-2B04
- Where
- 18 sites in United States, Hungary and 3 more
- Volunteers
- 25 people
- Sponsor
- AbbVie
Influenza, Human, Pregnancy
Afluria Pregnancy Registry
The study is a population based prospective cohort study designed to collect data on pregnancy outcomes and events of interest among women immunized with Afluria during pregnancy.
- Conditions
- Influenza, Human, Pregnancy, Birth Defect
- Trial name
- NCT03442582
- Testing
- Afluria Influenza Vaccine
- Where
- United States
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- Seqirus
COVID-19
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.
This study will assess the safety and efficacy of a single dose of AZD7442(× 2 IM injections) compared to placebo for the prevention of COVID-19.
- Trial name
- PROVENT (NCT04625725)
- Testing
- AZD7442
- Where
- 89 sites in United States, Belgium and 3 more
- Volunteers
- 5,197 people
- Sponsor
- AstraZeneca
Sinusitis
Application of Ectoin® Rhinitis Nasal Spray in Patients With Acute Rhinosinusitis
This is a comparative, open label, parallel group, non interventional study to further demonstrate the effectiveness and tolerability of Ectoin® Rhinitis Nasal Spray.
- Trial name
- SNS01 (NCT01684540)
- Testing
- Medical Device, Drug-like, Sinupret forte
- Where
- 6 sites in Germany
- Volunteers
- 66 people
- Sponsor
- Bitop AG
COVID-19
Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine
In this trial, a single-arm, open-label study design will be used to evaluate the safety and tolerability after vaccination with escalating doses of the investigational vaccine (Recombinant COVID-19 Vaccine (chimpanzee adenovirus…
- Trial name
- NCT05706324
- Testing
- Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
- Where
- Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
Pneumonia, Pelvic Inflammatory Disease
Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
To collect the efficacy and safety information of Azithromycin IV related to their appropriate use in daily practice
- Trial name
- RESCUE (NCT01671280)
- Testing
- Azithromycin IV
- Volunteers
- 403 people
- Sponsor
- Pfizer
COVID-19 Pandemic
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the safety and immunogenicity of SCTV01E in population of different ages who have been vaccinated against COVID-19.
- Trial name
- SCTV01E (NCT05652543)
- Testing
- SCTV01E
- Where
- 4 sites in China
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019.
- Trial name
- NCT04712110
- Testing
- TAK-019
- Where
- 2 sites in Japan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
Non-Inferiority Study Comparing the Subunit Vaccines Influvac and Agrippal in China
In the study Influvac will be compared to Agrippal, another subunit influenza vaccine that is already on the market in China. The main objective of the study is to show that both vaccines are comparable with regard to efficacy.
- Trial name
- NCT00325260
- Testing
- Influvac; subunit influenza vaccine
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Respiratory Syncytial Virus (RSV), Lower Resp Tract Infection
A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (sisunatovir). Sisunatovir is developed as potential treatment of Respiratory Syncytial Virus (RSV) infections.
- Trial name
- REVIRAL 1 (NCT04225897)
- Testing
- RV521
- Where
- 60 sites in Argentina, Canada and 13 more
- Volunteers
- 51 people
- Sponsor
- Pfizer
Pneumococcal Infections, Streptococcus Pneumoniae Infections
Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults
This study is designed to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adult volunteers.
- Conditions
- Pneumococcal Infections, Streptococcus Pneumoniae Infections, Pneumococcal Pneumonia
- Trial name
- NCT01444352
- Testing
- Pneumococcal vaccine Formulation 1, Pneumococcal vaccine Formulation 2, Pneumococcal vaccine Formulation 3
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19, SARS-CoV2
Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04468958
- Testing
- SAB-185, Normal saline
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- SAb Biotherapeutics, Inc.